RT Journal Article
T1 Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain.
A1 Rios-Martin, Juan Jose
A1 Rodriguez-Salas, Nuria
A1 Vazquez-Doval, Francisco Javier
A1 Llombart, Beatriz
A1 Rojas-Ferrer, Nohelia
A1 Gonzalez-Vela, M Carmen
A1 Zulueta, Teresa
A1 Monteagudo, Carlos
A1 Aneiros-Fernandez, Jose
A1 Beato, Maria Jose
A1 Carrillo, Rosario
A1 Silva-Carmona, Mary Yohana
A1 Ayala, Maria
A1 Gallego, Elena
A1 Rodriguez-Peralto, Jose Luis
A1 Fraga-Fernandez, Javier
A1 Fernandez-Figueras, Maria Teresa
A1 Barranco, Carlos
A1 Cordoba, Alicia
A1 Sanz-Zorrilla, Alicia
A1 Ferrer, Berta
A1 Funez, Rafael
A1 Santonja, Carlos
A1 Saus, Carlos
A1 Idoate, Miguel Angel
A1 Santos-Briz, Angel
A1 Onrubia, Jose
A1 Pinedo, Fernando
A1 de-Las-Peñas, Ramon
K1 Clinical
K1 Features Spain
K1 Merkel cell carcinoma
K1 Pathological
AB Merkel cell carcinoma (MCC) is a malignant skin cancer with a 5-year survival rate of approximately 50%. Knowledge of MCC has increased in recent years mostly due to improved diagnosis techniques. In Spain there is lack of information regarding the incidence and tumour characteristics, and the treatment approaches are not standardised. The objective of this study was to provide information of the clinical and epidemiological characteristics of MCC patients in Spain. Retrospective, observational study involving 192 patients from 25 Spanish hospitals. Evaluated variables included overall survival and incidence rate of Merkel cell polyomavirus, in patients diagnosed from 2012 to 2016. The Spanish incidence rate was estimated 0.32/100,000 inhabitants/year, with variations according to geographical regions, being slightly higher in areas with greater sunlight exposure. In total, 61.5% of tumours showed expansive growth (progressive growth of the tumour), 78.6% showed localisation in UV-exposed skin. 97.4% of patients were diagnosed by excisional biopsy. Surgery was the first line treatment in 96.6% of patients, radiotherapy in 24.6%, and chemotherapy in 6.3%. These treatments were not mutually exclusive. Median overall survival was 38.3 months (78.4% at 12 months and 60% at 24 months). MCPyV was present in 33.8% of patients. The incidence of MCC in Spain is one of the highest in Europe, with a slight predominance in men. The sample has shown that a biopsy is available for diagnosis in most cases. Moreover, the treatment is surgical when the tumour is localized and is associated with lymphadenectomy, and/or it is radiotherapy if widespread.
PB Elsevier
YR 2021
FD 2021-12-15
LK http://hdl.handle.net/10668/22068
UL http://hdl.handle.net/10668/22068
LA en
NO Ríos-Martín JJ, Rodriguez-Salas N, Vázquez-Doval FJ, Llombart B, Rojas-Ferrer N, González-Vela MC, et al. Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain. Cancer Epidemiol. 2022 Feb;76:102081
DS RISalud
RD Apr 8, 2025